comparemela.com

Latest Breaking News On - John vandermosten - Page 12 : comparemela.com

TLSA: Nasally-administered Foralumab Trial in SPMS Patient

By John Vandermosten, CFA NASDAQ:TLSA | LSE:TILS READ THE FULL TLSA RESEARCH REPORT On May 25, 2021, Tiziana Life Sciences PLC (NASDAQ:TLSA ) (LSE:TILS) announced that it had initiated a trial through the Individual Patient Expanded Access Program (EAP) of foralumab in a Secondary Progressive Multiple Sclerosis (SPMS) patient. This follows a previous release in late March that first introduced the effort that was cleared under the EAP. The first.

Achieve Life Sciences, Inc to Host Virtual Non-Deal Roadshow on Tuesday, April 27, 2021

Achieve Life Sciences, Inc. to Host Virtual Non-Deal Roadshow on Tuesday, April 27, 2021 SEATTLE, WA and VANCOUVER, BC / ACCESSWIRE / April 22, 2021 / Achieve Life Sciences, Inc. (NASDAQ:ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced it will be hosting a Virtual Non-Deal Roadshow on Tuesday, April 27, 2021, at 9:00AM EDT. Achieve s Chief Executive Officer, John Bencich, will be providing a corporate presentation and participating in a Q&A session with John Vandermosten, Senior Biotech Analyst at Zacks Small Cap Research. To access the presentation, please visit https://www.issuerdirect.com/snn/ndr/achieve-life-sciences.

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.